What medication options and dosing are recommended for treating insomnia in adults after attempting non‑pharmacologic therapy?

Insomnia Medication Recommendations

For adults with chronic insomnia who have failed non-pharmacologic therapy, start with short-to-intermediate acting benzodiazepine receptor agonists (zolpidem, eszopiclone, zaleplon) or ramelteon as first-line pharmacotherapy, with specific agent selection based on whether the primary complaint is sleep onset versus sleep maintenance. 1

First-Line Pharmacologic Options

The 2017 AASM guideline provides the most recent evidence-based framework for medication selection:

For Sleep Onset Insomnia:

• Zaleplon 10 mg at bedtime (very short half-life, minimal next-day effects) 1
• Zolpidem 10 mg at bedtime (5 mg in elderly/debilitated) 1
• Ramelteon 8 mg at bedtime (non-scheduled, useful for substance abuse history) 1
• Triazolam 0.25 mg at bedtime (0.125 mg in elderly; note: associated with rebound anxiety, not first-line) 1

For Sleep Maintenance Insomnia:

• Suvorexant (orexin receptor antagonist) - newer agent with evidence for maintenance insomnia 1
• Eszopiclone 2-3 mg at bedtime (1 mg in elderly; longer half-life) 1
• Doxepin 3-6 mg at bedtime (specifically for maintenance insomnia) 1

For Both Sleep Onset AND Maintenance:

• Eszopiclone 2-3 mg 1
• Zolpidem 10 mg (or 12.5 mg controlled-release formulation) 1
• Temazepam 15-30 mg at bedtime (7.5 mg in elderly) 1

Critical Prescribing Framework

All pharmacotherapy should be accompanied by patient education covering: 2

• Treatment goals and realistic expectations
• Safety concerns (no alcohol, adequate sleep opportunity of 7-8 hours)
• Risk of next-day impairment and "sleep-driving" behaviors
• Potential for dosage escalation and rebound insomnia
• Concurrent cognitive-behavioral therapy when possible

Follow-up schedule: Every few weeks initially to assess effectiveness, side effects, and ongoing need 2

Sequential Treatment Algorithm

If the initial agent fails, the guideline recommends this stepwise approach 2:

1. Try an alternate BzRA or ramelteon - Different pharmacokinetics may work better (e.g., switch from short-acting zaleplon to longer-acting eszopiclone if maintenance insomnia emerges)

2. Consider sedating antidepressants - Particularly when comorbid depression/anxiety exists:

   • Trazodone (though 2017 guideline suggests NOT using it) 1
   • Doxepin 3-6 mg (has positive evidence for maintenance insomnia) 1
   • Mirtazapine (note: weight gain risk)
   • Amitriptyline (anticholinergic burden, especially problematic in elderly)

3. Combination therapy - BzRA/ramelteon PLUS sedating antidepressant

4. Other agents for refractory cases with comorbidities:

   • Gabapentin (if comorbid pain/restless legs)
   • Quetiapine or olanzapine (if comorbid psychiatric condition; NOT for primary insomnia due to metabolic risks)

Important Contraindications and Cautions

DO NOT use (based on lack of efficacy/safety data): 1

• Diphenhydramine or OTC antihistamines (weak recommendation against)
• Melatonin supplements (weak recommendation against)
• Trazodone (2017 guideline recommends against, though widely prescribed off-label)
• Tiagabine (weak recommendation against)
• Valerian or herbal supplements
• Barbiturates or chloral hydrate (absolutely contraindicated) 2

Dose reductions required for:

• Elderly patients (typically 50% dose reduction)
• Hepatic impairment
• Women (FDA recommends lower zolpidem doses: 5 mg vs 10 mg for men)

Use extreme caution with:

• Sleep apnea or respiratory compromise
• Depression with suicidal ideation
• History of substance abuse (consider ramelteon or suvorexant instead)
• Concurrent CNS depressants

Duration of Treatment

• Short-term use (≤4 weeks): Can discontinue abruptly 2
• Medium/long-term use (>2-4 weeks): Taper gradually at 10-25% weekly dose reduction to avoid rebound insomnia 3
• Chronic use: May be indicated for severe/refractory insomnia, but requires consistent follow-up, ongoing effectiveness assessment, and monitoring for adverse effects 2
• Intermittent dosing: Can use 3 nights per week or as-needed rather than nightly to reduce tolerance risk 2

Key Divergence in Evidence

The 2017 AASM guideline 1 specifically recommends AGAINST trazodone, despite it being one of the most commonly prescribed off-label agents for insomnia. The older 2008 guideline 2 listed it as a second-line option for comorbid depression. Given the more recent evidence, avoid trazodone as monotherapy for insomnia.

The 2016 American College of Physicians guideline 4 takes a more conservative stance, recommending CBT-I as initial treatment (strong recommendation) and suggesting shared decision-making for pharmacotherapy only after CBT-I failure, noting insufficient evidence for long-term safety.

Newer Agents

Dual orexin receptor antagonists (DORAs) represent a mechanistically different approach - they inhibit wakefulness rather than induce sedation 5:

• Suvorexant (approved, in 2017 AASM guideline)
• Lemborexant (approved post-guideline)
• Daridorexant (newest, 8-hour half-life, no rebound/withdrawal, minimal abuse potential) 5

These agents may have advantages in terms of next-day functioning and lack of dependence risk, though cost and insurance coverage may limit access.

Common Pitfalls to Avoid

1. Using antihistamines - Despite OTC availability, evidence does not support efficacy and anticholinergic burden is problematic, especially in elderly
2. Prescribing without addressing perpetuating factors - Sleep hygiene alone is insufficient but must accompany pharmacotherapy
3. Indefinite continuation without reassessment - Regular follow-up is mandatory
4. Ignoring comorbid sleep disorders - If treatment-resistant, consider polysomnography to rule out sleep apnea or periodic limb movements
5. Combining multiple sedating agents - Increases fall risk and cognitive impairment, particularly in elderly